Reolysin reovirus: ONC filed to begin a U.S. and Canadian Phase I/II dose escalation trial of Reolysin given intracerebrally to treat recurrent malignant glioma

Oncolytics Biotech Inc. (ONCY; TSE:ONC), Calgary, Alberta Product: Reolysin reovirus Business: Cancer Therapeutic category: Immune modulation Target: Tumor cells with an activated Ras pathway Descri...